Focus On CML

SPIRIT 2: Dasatinib Superior to Imatinib in Newly Diagnosed CML
December 09, 2014 – 
Results from a large phase 3 prospective randomized open-label trial, comparing imatinib 400 mg with dasatinib 100 mg daily, were presented by Stephen O'Brien, MD, professor of hematology, Newcastle University Medical School, Newcastle upon Tyne, England.
EPIC Trial Shows Ponatinib Effective in CML
December 09, 2014 – 
On Monday, the third day of the 56th Annual Meeting of the American Society of Hematology, held December 6-9, in San Francisco, Jeffrey H. Lipton, MD, PhD, chief, presented results from the EPIC trial, evaluating ponatinib in patients with newly diagnosed chronic phase chronic myelogenous leukemia.
Giora Sharf Discusses Ways to Represent the CML Patient Voice
December 08, 2014 – 
There are many ways patients with chronic myelogenous leukemia can ensure they are active participants in their own treatment, according to Giora Sharf, co-founder of the CML Advocates Network.
Dr Susanne Saussele Defines When Patients With CML Should Change Therapy
December 08, 2014 – 
Although guidelines from the National Comprehensive Cancer Network and recommendations from the European LeukemiaNet do not identify a failure time point for major molecular response in patients with chronic myelogenous leukemia, a study at the 56th Annual Meeting of the American Society of Hematology was able to pinpoint when treatment is not working.
Evaluating Safety, Efficacy, and Outcomes of TKIs in CML
December 08, 2014 – 
A poster session on the second day of the 56th annual meeting of the American Society of Hematology, held December 6-9, San Francisco, was dedicated to trials evaluating therapeutic options in chronic myelogenous leukemia. Data presented included safety, efficacy, managing comorbidities, and biological differences that drive response to therapy.
Jan Geissler Explains Differing Perceptions for Living With CML
December 08, 2014 – 
Perceptions of chronic myelogenous leukemia (CML) and how to live with it are very different for patients and physicians, and a strong dialogue is needed to overcome the disparity, according to Jan Geissler, co-founder of the CML Advocates Network.
Dr Giuseppe Saglio Compares Efficacy, Safety of Nilotinib With Imatinib for CML Patients
December 08, 2014 – 
Although nilotinib as a first-line therapy for chronic myelogenous leukemia is a more effective treatment than imatinib, nilotinib's side effects are too much for patients.
TKIs and Molecular Response in CML: the EURO-SKI Study
December 08, 2014 – 
On the second day at the Annual Meeting of the American Society of Hematology 2014, Francois-Xavier Mahon, MD, PhD, Bordeaux Hospital, INSERM 1035, Bordeaux, France, shared the results from the European LeukemiaNet Stop TKI (EURO-SKI) study; the trial used tyrosine kinase inhibitors (TKIs) in CML to define prognostic markers to increase the rate of patients in durable deep molecular response after stopping TKI.
Greg Stephens Offers Advice for the Newly Diagnosed CML Patient
December 07, 2014 – 
One of the reoccurring themes at the 56th Annual Meeting of the American Society of Hematology was the importance of proper monitoring, said Greg Stephens, executive director of the National CML Society.
Dr Elaine Fuchs Explains How Stem Cell Discoveries Fuel Cancer Therapeutics
December 07, 2014 – 
Isolating and comparing cancer stem cells with their normal counterparts has allowed researchers to identify hundreds of differences that can be used to target therapies, said Elaine Fuchs, PhD, an investigator at the Howard Hughes Medical Institute at the Rockefeller University.
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.